Skip to main content
. 2017 Feb 1;7(2):289–300.

Figure 4.

Figure 4

miR-92b targets PTEN. A. The predicted miR-92b binding sequence in the 3’UTR of PTEN mRNA is shown. Mutations are generated in the PTEN 3’UTR sequence at the complementary sites for the seed regions in miR-92b. B. Luciferase activity assays are performed in T98G and LN229 cells transfected with pGL3-wild-PTEN 3’UTR or pGL3-mutant-PTEN 3’UTR tighter with miR-92b or miRNA control or anti-miR-92b or anti-miRNA control (*P<0.05; **P<0.01; ***P<0.001). C. Western bolt analysis of PTEN expression in T98G and LN229 cells transfected with miR-92b or miRNA control or anti-miR-92b or anti-miRNA control after 48 h; GAPDH was used as an internal control. D. MTT assay is used to measure proliferation ability of T98G cells treated with miR-92b or PTEN siRNA or miR-92b and PTEN or their respective control. PTEN inhibition significantly decreases the rate of T98G cell growth, and miR-92b promotes glioma cell growth, while PTEN overexpression abrogates miR-92b-induced glioma cell rapid growth (*P<0.05, PTEN siRNA vs. scramble siRNA; miR-92b vs. miR-con; miR-92b+PTEN vs. miR-92b+vector).